Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758784 | 0.85 | GRIA3 (0.70) | GRIA3GRIA4HPGDRAB9ATAS1R3 | |
| SCHEMBL5759402 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDRAB9ATAS1R3 | |
| SCHEMBL5791567 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDRAB9ATAS1R3 | |
| SCHEMBL1809973 | 0.81 | GRIA3 (0.57) | GRIA3GRIA4HRH3MGLLCYP2C9 | |
| SCHEMBL5758316 | 0.81 | GRIA3 (0.97) | GRIA3GRIA4HPGDCYP1A2CYP3A4 | |
| SCHEMBL5756683 | 0.80 | GRIA3 (0.65) | GRIA3GRIA4HPGDMGLLTAS1R3 | |
| Farampator SCHEMBL677135 | 0.79 | GRIA3 (1.00) | GRIA3GRIA4HPGDCYP1A2CYP3A4 | |
| SCHEMBL5760125 | 0.79 | GRIA3 (1.00) | GRIA3GRIA4HPGDCYP1A2CYP3A4 | |
| Cx-717 SCHEMBL243542 | 0.78 | GRIA3 (0.76) | GRIA3GRIA4HPGDALDH1A1 | |
| SCHEMBL5756335 | 0.78 | GRIA3 (0.62) | GRIA3GRIA4HPGDRAB9ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1428534-B1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | UNIV CALIFORNIA (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1428534-A1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | The Regents of the University of California (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6730677-B2 | TREATING MEMORY IMPAIRMENT; ENHANCE EXCITATORY SYNAPTIC ACTIVITY IN ORDER TO RESTORE AN IMBALANCE BETWEEN BRAIN SUBREGIONS, AS IN TREATMENT OF SCHIZOPHRENIA OR SCHIZOPHRENIFORM BEHAVIOR. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | GRIA3 11/4885GRIA4 4/4885HPGD 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.